Promis­es of a next-gen se­quenc­ing ap­proach earn El­e­ment Bio­sciences a hefty Se­ries C. Is an IPO next?

It took more than a decade and bil­lions of dol­lars for sci­en­tists to se­quence the first hu­man genome back in 2003. While DNA se­quenc­ing costs much less to­day, a slew of com­pa­nies is work­ing on next-gen ap­proach­es to save re­searchers time and mon­ey. El­e­ment Bio­sciences is one of them, and on Tues­day, the com­pa­ny un­veiled a $276 mil­lion round.

The Se­ries C brings El­e­ment’s to­tal raise to about $400 mil­lion. While the com­pa­ny de­clined an in­ter­view with End­points News, it ap­pears as though CEO Mol­ly He could have the com­pa­ny’s S-1 pa­pers in her back pock­et.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER